Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KANWAL PRATAP SINGH RAGHAV and VAN KARLYLE MORRIS.
KANWAL PRATAP SINGH RAGHAV
Connection Strength
2.026
VAN KARLYLE MORRIS
  1. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun. 2023 12 11; 3(12):2510-2517.
    View in: PubMed
    Score: 0.234
  2. Bintrafusp alfa, an anti-PD-L1:TGF-? trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun. 2022 09; 2(9):979-986.
    View in: PubMed
    Score: 0.215
  3. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol. 2022 Apr; 13(2):647-656.
    View in: PubMed
    Score: 0.208
  4. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949.
    View in: PubMed
    Score: 0.151
  5. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
    View in: PubMed
    Score: 0.141
  6. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncol. 2024 Nov 01; 10(11):1519-1529.
    View in: PubMed
    Score: 0.062
  7. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers (Basel). 2024 Feb 09; 16(4).
    View in: PubMed
    Score: 0.059
  8. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer. 2023 11; 194:113356.
    View in: PubMed
    Score: 0.058
  9. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023 Feb 13; 7(1):16.
    View in: PubMed
    Score: 0.055
  10. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol. 2023 01 20; 41(3):460-471.
    View in: PubMed
    Score: 0.054
  11. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist. 2022 11 03; 27(11):952-957.
    View in: PubMed
    Score: 0.054
  12. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open. 2022 10 03; 5(10):e2236357.
    View in: PubMed
    Score: 0.054
  13. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).
    View in: PubMed
    Score: 0.053
  14. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. 2023 05 01; 277(5):813-820.
    View in: PubMed
    Score: 0.053
  15. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2022 03; 21(1):e28-e37.
    View in: PubMed
    Score: 0.050
  16. Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.049
  17. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res. 2021 06 01; 27(11):3039-3049.
    View in: PubMed
    Score: 0.049
  18. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021 02 01; 39(4):285-294.
    View in: PubMed
    Score: 0.048
  19. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 12; 17(12):757-770.
    View in: PubMed
    Score: 0.046
  20. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.
    View in: PubMed
    Score: 0.046
  21. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020 03; 19(1):48-56.e2.
    View in: PubMed
    Score: 0.044
  22. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
    View in: PubMed
    Score: 0.043
  23. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019 06 15; 125(12):2002-2010.
    View in: PubMed
    Score: 0.042
  24. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019 02 01; 30(2):243-249.
    View in: PubMed
    Score: 0.042
  25. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. 2018 12; 17(4):e699-e709.
    View in: PubMed
    Score: 0.040
  26. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
    View in: PubMed
    Score: 0.039
  27. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.